30493-06-2

Usage

Chemical class

imidazo[1,2-a]pyridine derivatives

Type of compound

carbaldehyde

Contains

4-chlorophenyl group

Core structure

imidazo[1,2-a]pyridine

Potential applications

pharmaceutical industry (drug development, therapeutic agents)

Value in research

medicinal chemistry, drug discovery

Importance

investigation of potential uses and properties in various applications

Upstream product

• 1284210-49-6 tert-butyl prop-2-yn-1-yl(pyridin-2-yl)carbamate 
• 637-87-6 1-Chloro-4-iodobenzene 
• 6188-43-8 imidazo[1,2-a]pyridine-3-carbaldehyde 
• 38427-94-0 N-(tert-butoxycarbonyl)-2-aminopyridine 
• 117459-95-7 N-(prop-2-yn-1-yl)pyridin-2-amine 
• 38922-74-6 2-(4-chlorophenyl)imidazolo[1,2-a]pyridine 
• 68-12-2 N,N-dimethyl-formamide 
• 504-29-0 2-aminopyridine 
• 1075-77-0 4-chlorocinnamaldehyde 
• 110-18-9 N,N,N,N,-tetramethylethylenediamine 
• 79-37-8 oxalyl dichloride 
• 5857-45-4 3-methylimidazo[1,2-α]pyridine 
• 99-91-2 para-chloroacetophenone 
• 536-38-9 4-chlorobenzoylmethyl bromide 

Downstream Products

• 1357622-10-6 (2E)-3-(2-(4-chlorophenyl)imidazo[1,2-a]pyridin-3-yl)-1-(4-methylsulfonylphenyl)prop-2-en-1-one 
• 1357622-22-0 6-(2-(4-chlorophenyl)imidazo[1,2-a]pyridin-3-yl)-4-[4(methylsulfonyl)phenyl]pyrimidin-2(1H)-one 
• 1357622-20-8 6-(2-(4-chlorophenyl)imidazo[1,2-a]pyridin-3-yl)-4-(4-chlorophenyl)pyrimidin-2(1H)-one 
• 1357622-07-1 (2E)-3-(2-(4-chlorophenyl)imidazo[1,2-a]pyridin-3-yl)-1-(4-chlorophenyl)prop-2-en-1-one 
• 1357622-14-0 6-(2-(4-chlorophenyl)imidazo[1,2-a]pyridin-3-yl)-4-phenylpyrimidin-2(1H)-one 
• 1357621-96-5 (2E)-3-(2-(4-chlorophenyl)imidazo[1,2-a]pyridin-3-yl)-1-phenyl-prop-2-en-1-one 
• 1357622-15-1 6-(2-(4-chlorophenyl)imidazo[1,2-a]pyridin-3-yl)-4-(4-methylphenyl)pyrimidin-2(1H)-one 
• 1357621-97-6 (2E)-3-(2-(4-chlorophenyl)imidazo[1,2-a]pyridin-3-yl)-1-(4-methylphenyl)prop-2-en-1-one 
• 1357622-13-9 (2E)-3-(2-(4-chlorophenyl)imidazo[1,2-a]pyridin-3-yl)-1-(4-nitrophenyl)prop-2-en-1-one 
• 1357622-25-3 6-(2-(4-chlorophenyl)imidazo[1,2-a]pyridin-3-yl)-4-(4-nitrophenyl)pyrimidin-2(1H)-one 
• 1357622-21-9 6-(2-(4-chlorophenyl)imidazo[1,2-a]pyridin-3-yl)-4-(3-chlorophenyl)pyrimidin-2(1H)-one 
• 1357622-09-3 (2E)-3-(2-(4-chlorophenyl)imidazo[1,2-a]pyridin-3-yl)-1-(3-chlorophenyl)prop-2-en-1-one 
• 1357622-19-5 6-(2-(4-chlorophenyl)imidazo[1,2-a]pyridin-3-yl)-4-(2,4-dichlorophenyl)pyrimidin-2(1H)-one 
• 1357622-05-9 (2E)-3-(2-(4-chlorophenyl)imidazo[1,2-a]pyridin-3-yl)-1-(2,4-dichlorophenyl)prop-2-en-1-one 

Relevant academic research and scientific papers

One-pot multicomponent synthesis of novel substituted imidazo[1,2-a]pyridine incorporated thiazolyl coumarins and their antimicrobial activity

A series of novel substituted imidazo[1,2-a]pyridine incorporated thiazolyl coumarin derivatives (4a, 4b, 4c, 4d, 4e, 4f, 4g, 4h, 4i, 4j, 4k, 4l, 4m, 4n, 4o, 4p, 4q, 4r, 4s, 4t) were synthesized in good yields via one-pot multicomponent condensation of su

Copper-catalyzed intramolecular dehydrogenative cyclization: Direct access to sensitive formyl-substituted imidazo[1,2-a]pyridines

A direct method for the synthesis of formyl-substituted imidazo[1,2-a]pyridines was achieved easily from cyclization of aminopyridines and cinnamaldehydes via copper catalysis. This oxidative cyclization process involved direct C-H bond functionalization, and C-C/C-N bond formation. In this transformation, the sensitive aldehyde group was preserved under oxidative conditions.

Imidazopyridine linked triazoles as tubulin inhibitors, effectively triggering apoptosis in lung cancer cell line

A library of new imidazopyridine linked triazole hybrid conjugates (8a-r) were designed, synthesized and evaluated for their cytotoxicity against four cancer cell lines namely, human lung (A549), human prostate (DU-145), human colon (HCT-116) and breast (

Design, synthesis and biological evaluation of imidazopyridine-propenone conjugates as potent tubulin inhibitors

A library of imidazopyridine-propenone conjugates (8a-8u) were synthesized and evaluated for their antitumor activity against four human cancer cell lines, namely, prostate (DU-145), lung (A549), cervical (Hela) and breast (MCF-7) cancer cell lines. These conjugates showed good to moderate activity against the tested cell lines. Among them, two conjugates (8m and 8q) showed significant antiproliferative activity against the human lung cancer cell line (A549) with IC50 values of 0.86 μM and 0.93 μM, respectively. Flow cytometry analysis revealed that these compounds arrested the cell cycle at the G2/M phase in the human lung cancer cell line (A549), inhibiting tubulin polymerization leading to apoptosis. Further, Hoechst staining, decrease in mitochondrial membrane potential and Annexin V-FITC assay suggested that the cell death was due to apoptosis induction. Overall, the present investigation demonstrated that the synthesized imidazopyridine-propenone conjugates are promising tubulin inhibitors and apoptotic inducers.

Synthesis, Molecular Docking, BSA, and In Vitro Reactivation Study of Imidazopyridine Oximes Against Paraoxon Inhibited Acetylcholinesterase

Aim: To synthesize and evaluate the fused heterocyclic imidazo[1,2-a]pyridine based oxime as a reactivator against paraoxon inhibited acetylcholinesterase. Background: Organophosphorus compounds (OPs) include parathion, malathion, chlorpyrifos, monocrotop

SUBSTITUTED DIAZAHETERO-BICYCLIC COMPOUNDS AND THEIR USE

The present application relates to novel (imidazo[1,2-a]pyridin-3-yl)methyl-substituted diazaheterobicyclic compounds, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and/or prevention of diseases, and to th

Copper- A nd DMF-mediated switchable oxidative C-H cyanation and formylation of imidazo[1,2-: A] pyridines using ammonium iodide

The cyanation and formylation of imidazo[1,2-a]pyridines were developed under copper-mediated oxidative conditions using ammonium iodide and DMF as a nontoxic combined cyano-group source and DMF as a formylation reagent. Mechanistic studies indicate that the cyanation of imidazo[1,2-a]pyridines proceeds through a two-step sequence: Initial iodination and then cyanation. The cyanation has a broad substrate scope and high functional group tolerance, and can be safely conducted on a gram scale. A novel copper-mediated formylation using the widely available DMF as the formylation reagent and environmentally friendly molecular oxygen as the oxidant has also been developed. This protocol also provided a convenient approach for the synthesis of clinically used saripidem. This journal is

2-PHENYL-3-(PIPERAZINOMETHYL)IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AS BLOCKERS OF TASK-1 AND TASK-2 CHANNELS, FOR THE TREATMENT OF SLEEP-RELATED BREATHING DISORDERS

The present application relates to novel 2-phenyl-3-(piperazinomethyl)imidazo[1,2-a]pyridine derivatives, to processes for their preparation, to their use alone or in combinations for the treatment and/or prevention of diseases, and to their use for prepa

Novel method for one-step construction of substituted 2-phenylimidazo[1,2-a]pyridine-3-aldehyde by using DMF (N,N-dimethylformamide) as formylation reagent

The invention discloses a novel method for one-step construction of substituted 2-phenylimidazo[1,2-a]pyridine-3-aldehyde by using DMF (N,N-dimethylformamide) as a formylation reagent. According to the method, substituted 2-phenylimidazo[1,2-a]pyridine is

Novel method for three-step construction drug molecular saripidem taking DMF as formylation reagent

The invention discloses a new method for three-step construction drug molecular saripidem taking DMF (N,N-dimethylformamide) as a formylation reagent. According to the novel method, 2-(4-chlorophenyl)imidazole(1,2-[alpha])pyridine is used as reaction raw